Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Identifying Predictors Of Response To Antipsychotics Using A Treatment Algorithm" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Identifying Predictors Of Response To Antipsychotics Using A Treatment Algorithm for you to read. Along with our medical data and news we also list Identifying Predictors Of Response To Antipsychotics Using A Treatment Algorithm Clinical Trials, which are updated daily. BioPortfolio also has a large database of Identifying Predictors Of Response To Antipsychotics Using A Treatment Algorithm Companies for you to search.
LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for Idiopathic Pulmonary Fibrosis (IPF).&...
ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ — Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company’s phase 3 clinical development program investigating the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of moderate-to-severe agitation in patients with Alzheimer&...
Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.
Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.
The first drug approved by the US Food and Drug Administration for the treatment for postpartum depression will be administered only to short term inpatients at specially approved sites, as the FDA...
“We are pleased to have achieved this important milestone toward making Elekta Unity available in Canada and expect that this important new treatment option will become available to The post Elekta Unity MR-linac receives medical device license from Health Canada appeared first on Compelo Medical Devices - Latest industry news and analysis.
NGM Biopharmaceuticals wants to be the next billion-dollar biotech on Wall Street, and so it's moving forward with an IPO that offers a springtime referendum on investor sentiment.
Eisai and Biogen's BAN2401 is to be put into Phase III trial for patients with early Alzheimer's disease.
Maternal and Child Health Journal (vol. 22, no. 12, 2018) is available online by subscription only. Articles include: “Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guidelines Uptake and Pediatric Transmission Between 2013 and … Read More
The National Pediculosis Association Continues its Leadership Role with New Educational Resources and the Tools to CombFirst! NEWTON, Mass. (PRWEB) March 26, 2019 No matter how each new generation of parents differs from its predecessors, one fact remains the same—sooner or later, they will be challenged by a lice infestation first identified at school, a childcare center, or camp. What’s cha...
Serum Institute of India completes a Phase 3 clinical trial with chemistry developed by Fina Biosolutions Fina Biosolutions is pleased to announce that the Serum Institute of India Private Limited (SIIPL), has completed a Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which the Serum Institute indicates all primary and sec...
Platform enables a diverse and multispecialty cancer care team to seamlessly collaborate on treatment plans for individual patients. OncoLens, a technology company serving cancer care programs has successfully closed a $1.35 million seed round. BIP Capital and Atlanta Technology Angels (ATA) led the round. The company will deploy the capital toward its...
HeartHero, the medical device startup and creator of the ultra-portable, affordable, and user-friendly automated external defibrillator (AED) was recently awarded a win at the American College of Cardiology’s 68th annual conference, ACC.19. Co-hosted with
There is currently controversy surrounding the use of laser treatment for port-wine stains (PWS) in children, with specific concerns around the repetitive use of general anesthesia. Initiating treatment during infancy has been proposed as a way of avoiding the need for general anesthesia, as it is easier to hold the patient still during treatment. In […] Source: 2 Minute Medicine
– In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions with Other Drugs and a High Barrier to Resistance Through 48 Weeks – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, ...
Media outlets report on news from Illinois, New Jersey, New York, Arizona, Tennessee, Louisiana, California, Pennsylvania, Texas, Maryland, Ohio, Georgia, Virginia and Washington.
“While some members of the Texas Legislature insist on attacking as well as offending women directly and indirectly, we will not join this charade by participating in this political grandstanding on issues which are already codified in Texas and Federal law,” the Texas lawmakers said. The boycott came in response to legislation that would explicitly require doctors to care for a baby who survi...
InControl Medical wins FDA clearance for new Attain, the first over-the-counter (OTC) non-implantable muscle stimulator designed for at-home use to help treat the approximately 60 million women in the U.S. suffering with stress, urge, mixed urinary incontinence and/or bowel incontinence. This is good news for all
Individuals with a calcium score above 100 should think twice about stopping aspirin. The higher the calcium score the more likely aspirin benefit exceeds harm. PALO ALTO, Calif. (PRWEB) March 26, 2019 Leading preventive cardiologists and academic cardiovascular specialists from the Society for Heart Attack Prevention and Eradication (SHAPE), (http://www.shapesociety.org), a non-profit organizati...
Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel...
ReviveMed is proud to announce that they are the recipient of the North American AI-Driven Next-Generation Metabolomics Technology Innovation Award from Frost & Sullivan as part of that company's 2018 Best Practices Awards. Frost & Sullivan, which has been providing a wide range of business consulting and market research analysis for over 50 years,...
Aphios Corporation today announced that it has been granted European Patent No. 2 925 315 B1 entitled “Bryoid Compositions, Methods of Making and Use Thereof,” for the composition of matter of a novel Bryostatin, method of manufacturing and for use in the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Down’s syndrome, H...
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radio-frequency (RF) spectroscopy technology. This press release features multimedia. View the full release here: https://
- Data demonstrate how an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy - Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors,
Researchers will highlight work in BRCA-deficient and rare pediatric cancers Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight its enhanced o...